Grey Wolf Therapeutics to Present First Clinical Data for GRWD5769 at 2024 ASCO Annual Meeting

Oxford, UK, May 29, 2024 – Grey Wolf Therapeutics, a biotechnology firm specializing in antigen modulation therapies, announced that initial clinical data for their primary immuno-oncology drug candidate, GRWD5769, will be showcased at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These findings derive from the ongoing Phase 1/2 clinical trial of GRWD5769, an innovative ERAP1 inhibitor targeting a variety of solid tumors. The ASCO event is scheduled to take place in Chicago from May 31 to June 4, 2024.

Presentation Details:
- Abstract Number: 2589
- Title: EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a Phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies
- Presenting Author: Dr. Thomas Lillie, Chief Medical Officer of Grey Wolf Therapeutics
- Poster Session: Development Therapeutics - Immunotherapy
- Date/Time: Saturday, June 1, 2024, 9:00 a.m. Central Time
- Location: Poster Hall – Hall A

Grey Wolf Therapeutics is pioneering a distinct immuno-oncology therapeutic approach through the use of a proprietary antigen modulation strategy. This method reveals novel and potent cancer antigens on tumor cell surfaces by using an oral inhibitor targeting endoplasmic reticulum aminopeptidases (ERAP1 or ERAP2), which are crucial proteins in the antigen presentation pathway. The inhibition of ERAP aims to trigger a new T cell response against tumors and prevent T-cell exhaustion, thus overcoming significant resistance mechanisms found in current immuno-oncology treatments.

The company's adaptive Phase 1/2 clinical trial of GRWD5769 is designed to assess the drug's safety, tolerability, and effectiveness. The trial also includes a planned combination therapy with the PD-1 inhibitor Libtayo® (cemiplimab) across various solid tumor types. Grey Wolf has recently expanded the trial to include a broader range of tumor types and initiated the first cohort for combination treatment.

About Grey Wolf Therapeutics:

Grey Wolf Therapeutics is a clinical-stage biotechnology company based in the UK and Australia, focusing on innovative drug discovery and development. The company is leading a novel therapeutic approach that centers on inhibiting ERAP1 and ERAP2, pivotal proteins in the antigen presentation pathway. This strategy aims to address immune dysfunction sources in both oncology and autoimmunity.

Their leading clinical candidate, GRWD5769, is a potent and selective oral ERAP1 inhibitor that has demonstrated potential in generating a strong and differentiated immune response against tumors. Additionally, Grey Wolf is advancing another ERAP1 inhibitor, GRWD0715, through preclinical development for autoimmune diseases. The company is also exploring neoantigen creation with an ERAP2 drug discovery program and targeting novel ERAP1 inhibitor-generated cancer antigens using MHC Class I directed therapies such as soluble T cell receptors (TCR) and TCR mimic bispecifics.

Grey Wolf Therapeutics continues to innovate in the field of antigen modulation, aiming to bring forward new therapeutic solutions to combat cancer and autoimmune diseases.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!